MOUNJARO
Waiting for a wonder drug? The weight just got longer
Eli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the drug in India in 2025, pending supply. The SEC recommends approval for pre-filled pens and vials, contingent on a phase-IV trial. The Drug Controller General of India will finalize the decision.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Wegovy should be treating more than just obesity
A new analysis highlights the significant cardiovascular benefits of Novo Nordisk's obesity drug Wegovy, showing improvements regardless of weight loss amount. This challenges perceptions of GLP-1 drugs, suggesting they could be viewed more as heart or metabolic medications. Improved access and understanding are crucial, as these drugs could impact various chronic conditions like kidney disease. Acknowledging these connections could lead to more effective treatment approaches and better outcomes.
Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billion
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 6%.
Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India
Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife for my appearance,” says Rajput. The drugs — Wegovy and Ozempic — which have the same ingredient, semaglutide, are all the rage ever since entrepreneur Elon Musk tweeted about it.
Eli Lilly in advanced clinical trials for its weight-loss pill
Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with Type 2 diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron.
Eli Lilly could launch obesity drug in India next year, CEO says
Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expected to reach $100 billion by the end of the decade. Lilly's drugs as well as Danish rival Novo Nordisk's in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, which were developed to control blood sugar in patients with type 2 diabetes.
Weight-loss drug may be launched in India next year, says Eli Lilly CEO David Ricks
US drug maker Eli Lilly plans to launch its weight-loss drugs Zepbound and Mounjaro in India next year. The company is considering pricing based on supply and volume expansion. Eli Lilly CEO David Ricks suggests focusing on digital services in the Indian healthcare industry to encourage innovation and improve access to healthcare.
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddy's, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.
Lilly rides wave of weight-loss drug demand, working to expand capacity
Shares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capitalization and most valuable healthcare company.
Wall St edges up with earnings, rate-cut expectations in focus
With around half of the S&P 500 companies having reported earnings, 80.4% have surpassed expectations, according to LSEG data last week. Overall S&P 500 earnings are now expected to have risen 7.8% in the fourth quarter from the year-ago quarter.
Budget Ozempic: Know about this weight loss trend on Tik Tok and its associated risks
In recent years, Ozempic, the winning diabetic drug is very much in demand, taking the world of weight loss by storm. Here's everything to know more
What other health conditions might weight-loss drugs treat?
New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.
Demand for weight-loss drugs fuels global rise in counterfeits
The increasing demand for weight-loss drugs such as Novo Nordisk's Ozempic has led to a rise in counterfeit versions of these medications. Law enforcement agencies, anti-counterfeiting organizations, and public health officials are collaborating to combat this issue. The popularity of weight-loss drugs has made them a target for criminal organizations. Novo Nordisk and Eli Lilly, the manufacturers of these drugs, are working with various agencies to identify and deter counterfeit products.
Corporate America weighs risks of the Ozempic effect
U.S. companies in various sectors, including food and beverage, medical devices, and dialysis services, are facing questions from investors regarding the impact of weight-loss drugs on their future sales. Companies like Conagra and Walmart are considering potential changes in portion sizes and expect increased revenues from health and wellness products due to the popularity of these drugs. On the other hand, companies like PepsiCo and Abbott Laboratories do not anticipate a significant impact on their sales.
Nestlé responds to weight-loss drug surge: Developing health aids for Ozempic, Wegovy users
Nestlé, the global food leader, is responding to the growing trend of appetite-suppressing weight-loss medications like Ozempic, Wegovy, and Mounjaro by innovating complementary products. These pharmaceutical advancements have prompted considerations regarding their potential influence on food sales and the financial performance of the food industry.
Hollywood's blockbuster weight loss drugs are becoming all the rage among affluent Indians
According to doctors and fitness experts, queries come in every other day from (well-heeled) patients, asking whether they can take the expensive, injectable drugs to shed those stubborn kilos. “It’s coming up in conversations everywhere. Patients ask me about it all the time,” says Ambrish Mithal, chairman and head of endocrinology, Max Healthcare. There are a lot of people interested in taking Ozempic because “the weight loss is so dramatic”, says Kiran Sethi, medical director, Isya Aesthetics.
Study finds drug used in diabetes treatment helped dieters shed 60 pounds
A new study shows that the diabetes drug Mounjaro, when combined with intensive diet and exercise, helped people with obesity or who are overweight lose at least a quarter of their body weight, or about 60 pounds on average.
Mounjaro: Here's all about the wonder antidiabetic medicine touted as the 'most powerful' weight-loss drug
Mounjaro is making headlines recently. This antidiabetic injectable drug has been touted as the most powerful weight-loss drug available. In this article, we will explore what Mounjaro is, how it works, and the potential benefits and risks associated with its use. Mounjaro has shown promise as a powerful weight-loss drug that can help to reduce body weight and improve blood sugar control.
Load More
